Melphalan: all 415 studies that test it
Page 3 of 5. Open to participants first (42), then studies with results posted, then the rest; newest registration first within each.
- HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD ProphylaxisActive, not recruitingNCT06001385Phase 2
- Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic SyndromeActive, not recruitingNCT05457556Phase 3
- Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MMStatus unknownNCT05438394Phase 1
- Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT05228249Phase 1
- 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic SyndromeActive, not recruitingNCT05139004Phase 1
- Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted GraftActive, not recruitingNCT05088356Phase 1
- An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular MelanomaActive, not recruitingNCT05022901Phase 3
- Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple MyelomaWithdrawnNCT05013437Early Phase 1
- Pharmacokinetic Study of Melphalan in Pediatric Hematopoietic Stem Cell TransplantationStatus unknownNCT04937634Phase 1
- HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation CyclophosphamideActive, not recruitingNCT04904588Phase 2
- A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow TransplantActive, not recruitingNCT04872595Phase 2
- Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain CancerWithdrawnNCT04521946Phase 1
- Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple MyelomaWithdrawnNCT04466475Phase 1
- A Prospective International Multicenter Clinical Trial for Eyes With Relapsed RetinoblastomaTerminatedNCT04455139Phase 2
- Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) PneumoniaStatus unknownNCT04380376Phase 2
- Intra-arterial Chemotherapy for RetinoblastomaCompletedNCT04342572Phase 1
- CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic MalignanciesWithdrawnNCT04282174Phase 2
- Inhalations of Ultra-low Doses of Melphalan for the Treatment of Non-cystic Fibrosis BronchiectasisStatus unknownNCT04278040Phase 2
- Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic MalignanciesStatus unknownNCT04264078Early Phase 1
- Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell TransplantationActive, not recruitingNCT04018937Phase 2
- a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma PatientsStatus unknownNCT04008888Not applicable
- STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMAActive, not recruitingNCT03829371Phase 4
- Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)Status unknownNCT03795597Phase 1/2
- Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL)CompletedNCT03792815Phase 2
- Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT03691376Phase 1
- High Dose Ascorbic Acid for Plasma Cell DisordersCompletedNCT03602235Phase 1
- TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple MyelomaWithdrawnNCT03506802Phase 1
- Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic SyndromeSuspendedNCT03494569Phase 1
- A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly PatientsActive, not recruitingNCT03352765Phase 1
- Study of Personalized Melphalan Dosing in the Setting of Autologous TransplantWithdrawnNCT03328936Phase 2
- MUK Nine b: OPTIMUM Treatment ProtocolActive, not recruitingNCT03188172Phase 2
- Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple MyelomaWithdrawnNCT03100877Phase 1/2
- Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk NeuroblastomaStatus unknownNCT03061656Phase 2
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance TherapyActive, not recruitingNCT03004287Phase 2
- Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed LymphomaWithdrawnNCT02961816Phase 2
- Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02960646Phase 1
- Conservative Treatments of RetinoblastomaActive, not recruitingNCT02866136Phase 2
- Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell TumorStatus unknownNCT02784054Phase 2
- Response Based Treatment for Children With Unresectable Localized Soft Tissue SarcomaStatus unknownNCT02784015Phase 2
- Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple MyelomaTerminatedNCT02773550Phase 4
- Allogeneic Stem Cell Transplantation for Children With CMLCompletedNCT02707393Phase 2/3
- Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed LymphomaWithdrawnNCT02701673Phase 1/2
- URMC Related Haplo-identical Donor BMTCompletedNCT02660281Phase 1
- A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid TumorsTerminatedNCT02653196Early Phase 1
- Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT02570542Phase 2
- Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or SarcomaWithdrawnNCT02507076Not applicable
- Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings SarcomaCompletedNCT02472392Phase 1
- Allogeneic Stem Cell Transplantation for Patients With Multiple MyelomaWithdrawnNCT02447055Early Phase 1
- Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple MyelomaActive, not recruitingNCT02415413Phase 2
- Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic CholangiocarcinomaTerminatedNCT02415036Phase 2
- A Pharmacokinetic Study of Melphalan in ChildrenCompletedNCT02390544Phase 1
- Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin LymphomaCompletedNCT02342782Phase 1
- Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell TransplantSuspendedNCT02333162Phase 1
- Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)TerminatedNCT02310997Phase 2
- GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory LymphomaTerminatedNCT02295722Phase 1/2
- Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma PatientsCompletedNCT02206425Phase 1/2
- Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular RetinoblastomaTerminatedNCT02116959Phase 1
- Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in MyelomaWithdrawnNCT02114502Phase 2
- Microdose Study of Melphalan, Bortezomib and DexamethasoneStatus unknownNCT02109861Early Phase 1
- A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple MyelomaCompletedNCT02072863Phase 1/2
- CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell TransplantActive, not recruitingNCT02061800Phase 1/2
- A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple MyelomaCompletedNCT01998971Phase 1
- Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood TransplantationStatus unknownNCT01983761Phase 1/2
- Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01936090Phase 1
- Busulfan and Melphalan Conditioning in Multiple MyelomaStatus unknownNCT01923935Phase 2
- A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP)TerminatedNCT01907009Phase 2/3
- High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin LymphomaActive, not recruitingNCT01840566Phase 1
- Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL AmyloidosisTerminatedNCT01807286Phase 1
- Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing SarcomaWithdrawnNCT01795430Not applicable
- Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin LymphomaWithdrawnNCT01769911Not applicable
- Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT01758328Phase 1
- Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide MaintenanceCompletedNCT01702831Phase 2
- Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).CompletedNCT01688401Phase 1
- Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous TransplantationCompletedNCT01660633Phase 2
- Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune DeficienciesActive, not recruitingNCT01652092Not applicable
- Intra-arterial Chemotherapy for Spinal MetastasesCompletedNCT01637766Phase 1
- NK Cells in Cord Blood TransplantationStatus unknownNCT01619761Phase 1
- Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple MyelomaTerminatedNCT01617213Phase 2
- Safety and Efficacy Study of High Dose Melphalan to Treat Multiple MyelomaStatus unknownNCT01572688Not applicable
- Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 YearsStatus unknownNCT01532856Phase 3
- Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity MelanomaWithdrawnNCT01531244Phase 1/2
- Risk-adapted Therapy for Primary Systemic (AL) AmyloidosisCompletedNCT01527032Phase 2
- High Dose Chemotherapy and Autologous Transplant for NeuroblastomaCompletedNCT01526603Not applicable
- Auto Transplant for High Risk or Relapsed Solid or CNS TumorsCompletedNCT01505569Not applicable
- Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-MatchTerminatedNCT01500161Phase 2
- Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic MalignanciesCompletedNCT01471067Phase 1
- Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid MalignanciesCompletedNCT01421173Phase 1
- Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular StageTerminatedNCT01393769Phase 2
- Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)CompletedNCT01279694Phase 1/2
- A Trial for Systemic Light-chain (AL) AmyloidosisCompletedNCT01277016Phase 3
- A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple MyelomaCompletedNCT01274403Phase 2
- Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma PatientsTerminatedNCT01116128Phase 2
- Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma PatientsCompletedNCT01093196Phase 3
- Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma SubjectsCompletedNCT01091831Phase 3
- Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT01085617
- Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.CompletedNCT01070862Phase 3
- BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)Status unknownNCT01063439Phase 2
- Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma PatientsCompletedNCT01063179Phase 3
- TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple MyelomaCompletedNCT01039025Phase 2
- Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell TumorsStatus unknownNCT00983398Phase 1/2